US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

First Trust Energy Alphadex Fund

19.94

+0.06000.30%

Post-market: 19.940.00000.00%18:42 EST

Volume:618.60K

Turnover:12.28M

Market Cap:317.05M

PE:- -

High:19.95

Open:19.87

Low:19.69

Close:19.88

52wk High:20.12

52wk Low:12.55

Shares:15.90M

Float Shares:15.90M

Volume Ratio:0.72

T/O Rate:3.89%

Dividend:0.42

Dividend Rate:2.09%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia

Press Release: Nu Holdings Ltd. Reports Third Quarter 2025 Financial Results

Press Release: Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results

Larimar Therapeutics Reports Third Quarter 2025 Financial Results

Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel

Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia

PacBio Enters High-Throughput Carrier Screening Market with Standalone HiFi Sequencing Assay for Challenging Genes

Larimar Therapeutics Reports Second Quarter 2025 Financial Results

Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich’s Ataxia

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/FXN/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"FXN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FXN\",,,,,undefined,":{"symbol":"FXN","market":"US","secType":"STK","nameCN":"First Trust Energy Alphadex Fund","latestPrice":19.94,"timestamp":1771621200000,"preClose":19.88,"halted":0,"volume":618595,"hourTrading":{"tag":"盘后","latestPrice":19.94,"preClose":19.94,"latestTime":"18:42 EST","volume":14,"amount":279.82,"timestamp":1771630944505,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.003018108651911583,"floatShares":15900002,"shares":15900002,"eps":0,"marketStatus":"Market Closed","change":0.06,"latestTime":"02-20 16:00:00 EST","open":19.87,"high":19.95,"low":19.69,"amount":12276320.886550002,"amplitude":0.013078,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":19.88,"sharesOutstanding":15900002,"nav":19.88,"aum":316092039.76,"dividendRate":0.020948,"bidAskSpread":0.000505,"preHourTrading":{"tag":"盘前","latestPrice":19.7,"preClose":19.88,"latestTime":"08:45 EST","volume":154,"amount":3079.18996,"timestamp":1771595109806,"change":-0.18,"changeRate":-0.009054,"amplitude":0.019618},"postHourTrading":{"tag":"盘后","latestPrice":19.94,"preClose":19.94,"latestTime":"18:42 EST","volume":14,"amount":279.82,"timestamp":1771630944505,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7158479557368594,"impliedVol":0.7714,"impliedVolPercentile":0.996},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FXN\",,,,,undefined,":{"symbol":"FXN","floatShares":15900002,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.7158479557368594,"shares":15900002,"dividePrice":0.4177,"high":19.95,"amplitude":0.013078,"preClose":19.88,"low":19.69,"week52Low":12.5483,"pbRate":"--","week52High":20.12,"institutionHeld":0,"latestPrice":19.94,"eps":0,"divideRate":0.020948,"volume":618595,"delay":0,"ttmEps":0,"open":19.87,"prevYearClose":16.47,"prevWeekClose":19.43,"prevMonthClose":18.35,"prevQuarterClose":16.47,"fiveDayClose":19.14,"twentyDayClose":17.6,"sixtyDayClose":16.31},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FXN\",params:#limit:5,,,undefined,":[{"date":"2025-12-12","symbol":"FXN","amount":0.1141,"announcedDate":"2025-12-11","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-12","defaultRemindTime":1765549800000,"name":"First Trust Energy AlphaDEX Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-31","payableDate":"2025-12-12","currency":"USD","dateTimestamp":1765515600000,"payDate":"2025-12-31"},{"date":"2025-09-25","symbol":"FXN","amount":0.099,"announcedDate":"2025-09-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-25","defaultRemindTime":1758807000000,"name":"First Trust Energy AlphaDEX Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-25","currency":"USD","dateTimestamp":1758772800000,"payDate":"2025-09-30"},{"date":"2025-06-26","symbol":"FXN","amount":0.0958,"announcedDate":"2025-06-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-26","defaultRemindTime":1750944600000,"name":"First Trust Energy AlphaDEX Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-30","payableDate":"2025-06-26","currency":"USD","dateTimestamp":1750910400000,"payDate":"2025-06-30"},{"date":"2025-03-27","symbol":"FXN","amount":0.1085,"announcedDate":"2025-03-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-27","defaultRemindTime":1743082200000,"name":"First Trust Energy AlphaDEX Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-31","payableDate":"2025-03-27","currency":"USD","dateTimestamp":1743048000000,"payDate":"2025-03-31"},{"date":"2024-12-13","symbol":"FXN","amount":0.0923,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-13","defaultRemindTime":1734100200000,"name":"First Trust Energy AlphaDEX Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-13","currency":"USD","dateTimestamp":1734066000000,"payDate":"2024-12-31"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FXN\",market:\"US\",,,undefined,":[{"executeDate":"2016-03-23","recordDate":"2016-03-28","paymentDate":"2016-03-31","value":0.0276,"currency":"USD"},{"executeDate":"2016-06-22","recordDate":"2016-06-24","paymentDate":"2016-06-30","value":0.0573,"currency":"USD"},{"executeDate":"2016-09-21","recordDate":"2016-09-23","paymentDate":"2016-09-30","value":0.0472,"currency":"USD"},{"executeDate":"2016-12-21","recordDate":"2016-12-23","paymentDate":"2016-12-30","value":0.0405,"currency":"USD"},{"executeDate":"2017-03-23","recordDate":"2017-03-27","paymentDate":"2017-03-31","value":0.0348,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FXN\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FXN\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2588172053","title":"Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia","url":"https://stock-news.laohu8.com/highlight/detail?id=2588172053","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588172053?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:00","pubTimestamp":1764594000,"startTime":"0","endTime":"0","summary":"– SGT-212 has been granted FDA Rare Pediatric Disease and Fast Track designations– – SGT-212 is the only dual route gene therapy in development to treat Friedreich’s ataxia – – FALCON Phase 1b clinica","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/01/3196939/0/en/Solid-Biosciences-Receives-FDA-Rare-Pediatric-Disease-Designation-for-SGT-212-Dual-Route-of-Administration-Gene-Therapy-for-Friedreich-s-Ataxia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","BK4130","FA","BK4139","FXN","IDN","SLDB","BK4539","BK4157","BK4535"],"gpt_icon":0},{"id":"2583510821","title":"Press Release: Nu Holdings Ltd. Reports Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2583510821","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583510821?lang=en_us&edition=fundamental","pubTime":"2025-11-14 06:00","pubTimestamp":1763071200,"startTime":"0","endTime":"0","summary":"Nu Holdings Ltd.  , one of the largest digital financial services platforms in the world, released its Third Quarter 2025 financial results today. Financial results are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards . The full earnings release has been made available on the Company's Investor Relations website at www.investors.nu, as well as the details of the Earnings Conference Call Nu will hold today at 5:00 pm Eastern time/7:00 pm Brasilia time.\"In Q3'25, we continued our strong trajectory of growth, expanding our customer base to 127 million with over 4 million net additions, and maintaining an activity rate above 83%. This solid growth and deeper engagement drove record revenues to over $4 billion and delivered $783 million in net income. As we continue scaling across markets, we're also building the next generation of our platform, redefining how we operate and how customers experience banking. Our vision is to become A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0143863784.USD","LU0456842615.SGD","LU0823046577.USD","BK4590","LU0265266980.USD","BK4588","IE00B1B80R65.USD","LU0265267285.USD","LU0256859116.SGD","LU0214875030.USD","LU0531970944.HKD","LU0788109048.HKD","LU1481012133.USD","LU0048575426.USD","LU0143863198.USD","LU0196696453.USD","LU1868838027.USD","LU0050427557.USD","LU0254981946.USD","BK4551","BK4206","LU0261950470.USD","BK4023","IEP","LU2125910500.SGD","FXN","GB00BDT5M118.USD","LU0449509016.USD","NU","NIM","LU0823046494.USD","LU1861220207.SGD","LU0251143458.SGD","LU2045819591.USD","LU2360107671.USD","LU0531971322.HKD","BK4587","BK4559","BK4585","BK4207","LU0396314238.USD","BK4543","LU0072463663.USD","LU0210535034.USD","LU0572108347.SGD","LU0106259046.USD","LU1868837565.USD","IE00BGV7N243.SGD","LU0196696701.USD"],"gpt_icon":1},{"id":"2581970996","title":"Press Release: Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2581970996","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581970996?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:01","pubTimestamp":1762376460,"startTime":"0","endTime":"0","summary":"Trials of DT-216P2 in Friedreich Ataxia  and DT-168 in Fuchs Endothelial Corneal Dystrophy  Ongoing. Cash and Securities of $206.0 Million as of Third Quarter 2025 Support Continued Pipeline Advancement. CARLSBAD, Calif., Nov. 05, 2025  -- Design Therapeutics, Inc. , a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced progress and updated milestones across its portfolio of GeneTAC candidates in addition to reporting financial results for the third quarter of 2025.\"The third quarter was marked by strong operational execution across our portfolio,\" said Pratik Shah, Ph.D., chairperson and chief executive officer of Design Therapeutics. \"Today we are excited to unveil DT-818 as our development candidate for the treatment of DM1, a debilitating neuromuscular disease with significant unmet medical need. With broad tissue distribution, significant splicing correction, and selectivity for mutant DMPK, we believe DT-818 has be","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","BK4130","R","BK4505","BK4232","BK4535","FXN","FA","BK4022","DSGN"],"gpt_icon":0},{"id":"2581722757","title":"Larimar Therapeutics Reports Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2581722757","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581722757?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:00","pubTimestamp":1762344000,"startTime":"0","endTime":"0","summary":"In the open label (OL) study, after 6-months of daily nomlabofusp administration, 100% of participants (n = 10) achieved skin FXN levels similar to asymptomatic carriersConsistent directional improvem","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/05/3181277/0/en/Larimar-Therapeutics-Reports-Third-Quarter-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","BK4130","BK4139","LU0882574139.USD","LU2237443978.SGD","FA","LU0971096721.USD","LU2746668461.USD","LU1363072403.SGD","LENZ","BK4535","BK4007","LU2237443549.SGD","LU0170899867.USD","LU2746668974.SGD","LU2237443382.USD","IE00BHPRN162.USD","CMC","LU2237443465.HKD","IE00B1BXHZ80.USD","LU0149725797.USD","LU0267386448.USD","BK4539","IE00BZ1G4Q59.USD","LU2237443895.HKD","IE00BKVL7J92.USD","LU2237443622.USD","FXN","IE00BFXG1179.USD"],"gpt_icon":0},{"id":"2575290651","title":"Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel","url":"https://stock-news.laohu8.com/highlight/detail?id=2575290651","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575290651?lang=en_us&edition=fundamental","pubTime":"2025-10-14 20:00","pubTimestamp":1760443200,"startTime":"0","endTime":"0","summary":"The Foresight Carrier Screen includes all conditions recommended by the American College of Medical Genetics and Genomics recommendationsSALT LAKE CITY, Oct.  14, 2025  (GLOBE NEWSWIRE) -- Myriad Gene","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/14/3166079/15459/en/Myriad-Genetics-Adds-F8-FXN-Genes-to-Foresight-Universal-Plus-Panel.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064131342.USD","MYGN","SG9999015945.SGD","SG9999015986.USD","UVV","SG9999018865.SGD","SGXZ81514606.USD","SG9999018857.SGD","SG9999014898.SGD","IE0002270589.USD","SG9999014880.SGD","FXN","LU0719512351.SGD","SG9999017495.SGD","BK4075","FA","BK4585","LU0353189680.USD","LU2087625088.SGD","LU0107464264.USD","LU0082616367.USD","SGXZ51526630.SGD","SGXZ31699556.SGD","LU0006306889.USD","SG9999015978.USD","LU0642271901.SGD","LU1861219969.SGD","LU1316542783.SGD","BK4539","BK4536","IE00BZ199S13.USD","BK4503","IE00B19Z3B42.SGD","BK4130","LU1814569148.SGD","BK4588","IE00B7SZLL34.SGD","IE00BFMHRM44.USD","BK4551","LU0127658192.USD","LU1988902786.USD","SG9999014914.USD","UBER","BK4139","LU0106261372.USD","BK4022","LU1983260115.SGD","BK4550","SG9999014906.USD","LU1861214812.USD"],"gpt_icon":0},{"id":"2571438767","title":"Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia","url":"https://stock-news.laohu8.com/highlight/detail?id=2571438767","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571438767?lang=en_us&edition=fundamental","pubTime":"2025-09-29 19:00","pubTimestamp":1759143600,"startTime":"0","endTime":"0","summary":"In 4 completed studies and the ongoing OL study, 65 participants received at least 1 dose of nomlabofusp, including 39 in the OL study, with 14 on treatment for at least 6 months and 8 for over 1 year","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/29/3157570/0/en/Larimar-Therapeutics-Announces-Positive-Data-from-Ongoing-Long-term-Open-Label-Study-and-Updates-to-Nomlabofusp-Program-for-Friedreich-s-Ataxia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","LU1169589451.USD","LU2237443465.HKD","IE00BFXG1179.USD","LU0267386448.USD","BK4139","LU0170899867.USD","IE00BHPRN162.USD","BK4181","LU0971096721.USD","BK4218","LU2237443895.HKD","LU2237443978.SGD","BK4023","IE00BZ1G4Q59.USD","LU1169590202.USD","LU2746668974.SGD","LU2237443382.USD","FA","CMC","FXN","LU1363072403.SGD","BK4130","IE00BKVL7J92.USD","LU0882574139.USD","LU2237443549.SGD","PK","PD","BK4006","BK4007","LENZ","LU2746668461.USD","BK4539","LU0149725797.USD","IE00B1BXHZ80.USD","LU2237443622.USD"],"gpt_icon":0},{"id":"2569178094","title":"PacBio Enters High-Throughput Carrier Screening Market with Standalone HiFi Sequencing Assay for Challenging Genes","url":"https://stock-news.laohu8.com/highlight/detail?id=2569178094","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569178094?lang=en_us&edition=fundamental","pubTime":"2025-09-22 21:05","pubTimestamp":1758546300,"startTime":"0","endTime":"0","summary":"Enhanced PureTarget portfolio replaces the need for multiple tests with single scalable solution for inherited disease screeningMENLO PARK, Calif., Sept.  22, 2025  (GLOBE NEWSWIRE) -- PacBio(NASDAQ: ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/22/3153978/16261/en/PacBio-Enters-High-Throughput-Carrier-Screening-Market-with-Standalone-HiFi-Sequencing-Assay-for-Challenging-Genes.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4121","BK4588","PACB","FXN"],"gpt_icon":0},{"id":"2559954530","title":"Larimar Therapeutics Reports Second Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2559954530","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559954530?lang=en_us&edition=fundamental","pubTime":"2025-08-14 19:00","pubTimestamp":1755169200,"startTime":"0","endTime":"0","summary":"Initial data from the 50 mg dose in the open label study and the adolescent PK run-in study planned for program update in September 2025Adolescent participants from the PK run-in study and patients wi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/14/3133297/0/en/Larimar-Therapeutics-Reports-Second-Quarter-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FXN","BK4007","BK4539","BK4181","FA","EMA","BK4535","BK4130","BK4139","BK4218","LENZ","BK4081","PK"],"gpt_icon":0},{"id":"2549549950","title":"Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich’s Ataxia","url":"https://stock-news.laohu8.com/highlight/detail?id=2549549950","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549549950?lang=en_us&edition=fundamental","pubTime":"2025-07-08 19:00","pubTimestamp":1751972400,"startTime":"0","endTime":"0","summary":"Nonclinical findings provide evidence of the mechanism of action of nomlabofusp and support the potential use of skin FXN concentrations as a novel surrogate endpoint for Larimar’s planned BLA submiss","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/08/3111592/0/en/Larimar-Therapeutics-Publishes-Nonclinical-Data-Supporting-the-Therapeutic-Potential-of-Nomlabofusp-in-Patients-with-Friedreich-s-Ataxia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4130","BK4535","FXN","BK4139","FA","BK4007","BK4539","LENZ"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":9,"code":"91000000","status":"200"}]}}